These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 12634887)

  • 1. The development of new medical treatments for acute decompensated heart failure.
    Teerlink JR
    Heart Fail Monit; 2002; 2(4):129-37. PubMed ID: 12634887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dyspnea as an end point in clinical trials of therapies for acute decompensated heart failure.
    Teerlink JR
    Am Heart J; 2003 Feb; 145(2 Suppl):S26-33. PubMed ID: 12594449
    [No Abstract]   [Full Text] [Related]  

  • 3. Optimizing outcomes in the patient with acute decompensated heart failure.
    Mehra MR
    Am Heart J; 2006 Mar; 151(3):571-9. PubMed ID: 16504617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacology of new agents for acute heart failure syndromes.
    Gheorghiade M; Teerlink JR; Mebazaa A
    Am J Cardiol; 2005 Sep; 96(6A):68G-73G. PubMed ID: 16181825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Newer approaches to the pharmacological management of heart failure.
    Rauch H; Motsch J; Böttiger BW
    Curr Opin Anaesthesiol; 2006 Feb; 19(1):75-81. PubMed ID: 16547437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure.
    Cleland JG; Nikitin N; McGowan J
    Expert Rev Cardiovasc Ther; 2004 Jan; 2(1):9-19. PubMed ID: 15038409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic therapy for acute heart failure.
    Tang WH
    Cardiol Clin; 2007 Nov; 25(4):539-51; vi. PubMed ID: 18063158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute effects of levosimendan on mitral regurgitation and diastolic function in patients with advanced chronic heart failure.
    Branzi G; Malfatto G; Villani A; Ciambellotti F; Revera M; Giglio A; Rosa FD; Facchini M; Parati G
    J Cardiovasc Med (Hagerstown); 2010 Sep; 11(9):662-8. PubMed ID: 20613551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
    Follath F
    Ital Heart J; 2003 May; 4 Suppl 2():34S-38S. PubMed ID: 14635368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New therapeutic choices in the management of acute congestive heart failure.
    Young JB
    Rev Cardiovasc Med; 2001; 2 Suppl 2():S19-24. PubMed ID: 12439358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The dual endothelin receptor antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failure.
    Schalcher C; Cotter G; Reisin L; Bertel O; Kobrin I; Guyene TT; Kiowski W
    Am Heart J; 2001 Aug; 142(2):340-9. PubMed ID: 11479476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of levosimendan on ventricular arrhythmias and prognostic autonomic indexes in patients with decompensated advanced heart failure secondary to ischemic or dilated cardiomyopathy.
    Flevari P; Parissis JT; Leftheriotis D; Panou F; Kourea K; Kremastinos DT
    Am J Cardiol; 2006 Dec; 98(12):1641-5. PubMed ID: 17145226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New pharmacologic therapies for acute heart failure.
    Tavares M; Rezlan E; Vostroknoutova I; Khouadja H; Mebazaa A
    Crit Care Med; 2008 Jan; 36(1 Suppl):S112-20. PubMed ID: 18158470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levosimendan: beyond its simple inotropic effect in heart failure.
    Antoniades C; Tousoulis D; Koumallos N; Marinou K; Stefanadis C
    Pharmacol Ther; 2007 May; 114(2):184-97. PubMed ID: 17363065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beneficial effects of early initiation of vasoactive agents in patients with acute decompensated heart failure.
    Saltzberg MT
    Rev Cardiovasc Med; 2004; 5 Suppl 4():S17-27. PubMed ID: 15627915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of nesiritide in patients with acute decompensated heart failure.
    DeWald TA; Hernandez AF
    Expert Rev Cardiovasc Ther; 2010 Feb; 8(2):159-69. PubMed ID: 20136602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure.
    Lilleberg J; Laine M; Palkama T; Kivikko M; Pohjanjousi P; Kupari M
    Eur J Heart Fail; 2007 Jan; 9(1):75-82. PubMed ID: 16829185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS).
    Teerlink JR; McMurray JJ; Bourge RC; Cleland JG; Cotter G; Jondeau G; Krum H; Metra M; O'Connor CM; Parker JD; Torre-Amione G; Van Veldhuisen DJ; Frey A; Rainisio M; Kobrin I;
    Am Heart J; 2005 Jul; 150(1):46-53. PubMed ID: 16084150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral levosimendan in patients with severe chronic heart failure --the PERSIST study.
    Nieminen MS; Cleland JG; Eha J; Belenkov Y; Kivikko M; Põder P; Sarapohja T
    Eur J Heart Fail; 2008 Dec; 10(12):1246-54. PubMed ID: 18945637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levosimendan: current status and future prospects.
    Archan S; Toller W
    Curr Opin Anaesthesiol; 2008 Feb; 21(1):78-84. PubMed ID: 18195615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.